Part, Chapter, Paragraph
1 II, 5. 1. 1| into cervical cancer.~ ~Prostate cancer: age is the strongest
2 II, 5. 1. 1| strongest risk factor for prostate cancer: development of this
3 II, 5. 3. 1| implication in screening activity; prostate and stomach cancers for
4 II, 5. 3. 3| cervix (ICD-9 code 180), prostate cancers (ICD-9 code 185),
5 II, 5. 3. 4| into cervical cancer.~ ~Prostate cancer: age is the strongest
6 II, 5. 3. 4| strongest risk factor for prostate cancer: development of this
7 II, 5. 3. 5| in the age class 20-44~ ~Prostate Cancer (ICD-9 185)~In 2006,
8 II, 5. 3. 5| deaths were estimated for prostate cancer in Europe (Ferlay
9 II, 5. 3. 5| al, 2007). Comparison of prostate cancer rates in European
10 II, 5. 3. 5| incidence) of positive prostate cancers prognosis.~Prostate
11 II, 5. 3. 5| prostate cancers prognosis.~Prostate cancer incidence seems to
12 II, 5. 3. 5| Europe.~ ~Figure 5.3.25. Prostate cancer (ICD9 185) standardized
13 II, 5. 3. 5| Figure 5.3.26. Trends of prostate cancer (ICD9 185) standardized
14 II, 5. 3. 5| standard)~Figure 5.3.27. Prostate cancer (ICD9 185) standardized
15 II, 5. 3. 5| Figure 5.3.28. Trends of prostate cancer (ICD9 185) standardized
16 II, 5. 3. 6| European relative survival for prostate cancer 5 years after diagnosis
17 II, 5. 3. 6| relative survival rates for prostate cancer differed greatly
18 II, 5. 3. 6| year relative survival for prostate cancer were seen in Estonia (
19 II, 5. 3. 6| 2003).~ ~Figure 5.3.35. Prostate cancer (ICD9 185) age-standardized
20 II, 5. 3. 6| breast (European mean: 79%), prostate (European mean: 76%) cancer
21 II, 5. 3. 6| with colorectal, breast, prostate cancers. The European mean
22 II, 5. 3. 6| cancer from 60% to 74%; prostate cancer from 40% to 68%).~
23 II, 5. 3. 7| establish whether screening for prostate cancer or lung cancer in
24 II, 5. 3. 7| for implementing lung or prostate cancer screening.~ ~
25 II, 9. 3. 1| instance, the incidence of prostate cancer is increasing due
26 II, 9. 3. 1| the breast, endometrium, prostate, testis, bowel, liver, kidney,
27 II, 9. 3. 1| 2004); the treatment of prostate cancer, which for many men
28 II, 9. 3. 1| are mainly due to either prostate problems or the side effects
29 II, 9. 3. 1| side effects of surgery for prostate problems.~ ~Brain function,
30 II, 9. 3. 1| ultrasounds, respectively. Prostate status should be assessed
31 II, 9. 3. 1| Lilja H, Hugosson J (2007): Prostate Cancer Screening Decreases
32 II, 9. 3. 1| Diagnosed with Advanced Prostate Cancer—Results from a Prospective,
33 II, 9. 3. 1| accessed 02.07)~ ~European Prostate Cancer Coalition: htt 1 (
34 II, 9. 3. 1| hormone agonist treatment for prostate carcinoma. Cancer 104(8):
35 II, 9. 4. 3| deaths after the age of 65. Prostate cancer is the most common
36 II, 9. 4. 3| Senkus-Konefka, 2004).~ ~Prostate Cancer. Deprivation incidence
37 II, 9. 5. 4| from their evaluation of prostate cancer and colorectal screening
38 III, 10. 2. 5| women and testicular- and prostate cancer in men. Testicular
39 III, 10. 3. 2| women and testicular- and prostate cancer in men. Testicular
40 III, 10. 5. 2| survival after diagnosis for prostate and lung cancer, and that,
41 IV, 13. 2. 3| atmosphere~Schizophrenia, prostate cancer, influenza~3,000 –
42 Key, Ap5. 0. 0| production~professionals~prostate~proteinuria~providers~pseudomonas~
